Pamela Carroll is Chief Operating Officer at Isomorphic Labs, a digital biology company that is accelerating drug discovery using artificial intelligence. Previously, Pamela was Chief Business Officer at Roivant Discovery, a biotechnology company pioneering a physics-driven approach to drug design. Prior to this, Pamela was SVP of Immuno-oncology at Genocea Biosciences where she spearheaded the development of vaccines and cell therapies. Pamela has also held the position of Vice President at Janssen Oncology/Johnson and Johnson Innovation leading strategic partnerships, newco investments, and academic collaborations. She successfully led drug discovery organizations in positions including Vice President of Roche Oncology Discovery and Head of Research at the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Center and Harvard Medical School. Earlier in her career Pamela served as Director of Cancer Pathways at Merck Research Laboratories and as Senior Investigator in Applied Genomics at Bristol Myers Squibb. Pamela received a BS in Biology from Saint Michael’s College in Vermont, a PhD in Cell Biology from Stony Brook University, and completed a postdoctoral fellowship at Stanford University.
